Clinical studies suggest that combining BRAF and MEK inhibitors impede drug resistance more than BRAF inhibitors alone and also minimize the risk of recurrence of skin diseases such as cutaneous squamous cell cancer (cSCC) [14,73]. This evidence concerns the gene BRAF and skin squamous cell carcinoma.